Ali Al Khazaali, MD
Endocrinology, Diabetes & Metabolism · Munster, INNPI 1093197451
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.3% of the total across 148 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,101 and has fallen 97.7% since, to $25 in 2025.
Across 148 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$497
- Novo Nordisk$470
- Insulet Corporation$361
- Abbott$265
- Medtronic$199
- Xeris Pharmaceuticals, Inc.$136
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,80593%
- Education$2037%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 30 | $497 |
| Novo Nordisk | 22 | $470 |
| Insulet Corporation | 12 | $361 |
| Abbott | 14 | $265 |
| Medtronic(2 entities) | 4 | $199 |
| Xeris Pharmaceuticals, Inc. | 7 | $136 |
| Amgen | 7 | $131 |
| AbbVie | 5 | $118 |
| Boehringer Ingelheim | 6 | $102 |
| Antares Pharma, Inc. | 4 | $78 |
| Corcept Therapeutics | 4 | $75 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Bayer | 3 | $44 |
| Lundbeck LLC | 3 | $43 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Dexcom, Inc. | 3 | $39 |
| AstraZeneca(2 entities) | 2 | $39 |
| Ultragenyx Pharmaceutical Inc. | 2 | $38 |
| IBSA Pharma Inc. | 2 | $34 |
| Ascendis Pharma Endocrinology Inc | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $18 |
| Mannkind Corporation | 1 | $18 |
| Amphastar Pharmaceuticals, Inc. | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Indivior Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$212
How this compares
$3,008 in reported general payments places this provider in the 60th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 192 | $372,420 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 69 | $98,673 |
| FarxigaDapagliflozin Propanediol | 70 | $84,185 |
| TrulicityDulaglutide | 45 | $78,151 |
| JardianceEmpagliflozin | 44 | $69,830 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $60,753 |
| MounjaroTirzepatide | 40 | $60,738 |
| ForteoTeriparatide | 12 | $58,437 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $35,094 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 19 | $34,507 |
| JanuviaSitagliptin Phosphate | 24 | $30,811 |
| Humalog Kwikpen U-100Insulin Lispro | 60 | $27,356 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 30 | $25,932 |
| TradjentaLinagliptin | 19 | $25,564 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 61 | $23,845 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $470 | $372,420192 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog | $497 | $199,891109 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $50 | $98,67369 claims |
| Boehringer IngelheimJardiance, Tradjenta | $102 | $95,39563 claims |
| AstraZenecaFarxiga | $39 | $84,18570 claims |
| AbbVieSynthroid | $118 | $6,52067 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $2,855299 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Munster
- Sana MeahMunster$12K
- Nabeel JabriMunster$11K
- Thottathil GopanMunster$8K
- Maali MilhemMunster$5K
- Milli GuptaMunster$4K
- Nirmal NairMunster$3K
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.